<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2709-7927</journal-id>
<journal-title><![CDATA[Acta Médica del Centro]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd centro]]></abbrev-journal-title>
<issn>2709-7927</issn>
<publisher>
<publisher-name><![CDATA[Hospital Provincial Clínico Quirúrgico Universitario Arnaldo Milián Castro]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2709-79272020000300304</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[¿Es la comorbilidad cardiovascular la causante de la elevación de la proteína C reactiva en pacientes positivos a la COVID-19?]]></article-title>
<article-title xml:lang="en"><![CDATA[Is cardiovascular comorbidity the cause of elevated C-reactive protein in Covid-19 positive patients?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Fernández]]></surname>
<given-names><![CDATA[Guillermo Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario &#8220;Celestino Hernández Robau&#8221;  ]]></institution>
<addr-line><![CDATA[Santa Clara Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<volume>14</volume>
<numero>3</numero>
<fpage>304</fpage>
<lpage>312</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2709-79272020000300304&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2709-79272020000300304&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2709-79272020000300304&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  estudios epidemiológicos recientes en China han informado un riesgo incrementado para el paciente con comorbilidades cardíacas en enfermos con el coronavirus 19.  Objetivos:  determinar el grado de asociación entre la morbilidad cardiovascular informada y la elevación de la proteína C reactiva en pacientes positivos al coronavirus 19.  Métodos:  se realizó un estudio descriptivo de carácter transversal a una muestra de 52 pacientes diagnosticados con el coronavirus 19 y admitidos en el Hospital &#8220;Celestino Hernández Robau&#8221; dedicado exclusivamente, durante la pandemia, a la atención de este tipo de pacientes. Se conformaron dos grupos en función de la presencia de comorbilidad cardiovascular.  Resultados:  entre las comorbilidades asociadas predominó la hipertensión arterial (32,7%), no hubo diferencias significativas entre la proporción de individuos con una proteína C reactiva elevada o normal con independencia del grupo en que se encontraban (p=0,79).  Conclusiones:  no existió asociación importante entre la morbilidad cardiovascular y la elevación de la proteína C reactiva en pacientes positivos al coronavirus 19.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  recent epidemiological studies in China have reported an increased risk for the patient with heart comorbidities in patients with the coronavirus 19.  Objectives:  to determine the degree of association between the reported cardiovascular morbidity and the elevation of C-reactive protein in patients positive for the coronavirus 19.  Methods:  a cross-sectional descriptive study was carried out on a sample of 52 patients diagnosed with coronavirus 19 and hospitalized in the &#8220;Celestino Hernández Robau&#8221; Hospital in Santa Clara city, Villa Clara, Cuba which was dedicated exclusively to the care of this type of patient during the pandemic. Two groups were formed based on the presence of cardiovascular comorbidity.  Results:  among the associated comorbidities, arterial hypertension predominated (32.7%), there were no significant differences between the proportion of individuals with a high or normal C-reactive protein, regardless of the group they were in (p=0.79).  Conclusions:  there was no important association between cardiovascular morbidity and C-reactive protein elevation in coronavirus-positive patients 19.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Covid-19]]></kwd>
<kwd lng="es"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[proteína C reactiva]]></kwd>
<kwd lng="es"><![CDATA[comorbilidad cardiovascular]]></kwd>
<kwd lng="en"><![CDATA[Covid-19]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[C reactive protein]]></kwd>
<kwd lng="en"><![CDATA[cardiovascular comorbidity]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures]]></article-title>
<source><![CDATA[J Med Virol]]></source>
<year>2020</year>
<volume>92</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>568-75</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[coronaviruses: genome structure, replication, and pathogenesis]]></article-title>
<source><![CDATA[J Med Virol]]></source>
<year>2020</year>
<volume>92</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>418-23</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Witteles]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Quertermous]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Rhee]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risks in patients with COVID-19: potential mechanisms and areas of uncertainty]]></article-title>
<source><![CDATA[Curr Cardiol Rep]]></source>
<year>2020</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>34</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[XW]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[ZC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients]]></article-title>
<source><![CDATA[Zhonghua Xin Xue Guan Bing Za Zhi]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rello]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bailén]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Benítez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gordillo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2004</year>
<volume>30</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2038-45</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batún Garrido]]></surname>
<given-names><![CDATA[JAJ]]></given-names>
</name>
<name>
<surname><![CDATA[García Padrón]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Salas Magaña]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proteína C reactiva como marcador de riesgo cardiovascular en una cohorte de pacientes con artritis reumatoide]]></article-title>
<source><![CDATA[Rev Cubana Reumatol]]></source>
<year>2016</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>111-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pepys]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Baltz]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein]]></article-title>
<source><![CDATA[Adv Immunol]]></source>
<year>1983</year>
<volume>34</volume>
<page-range>141-212</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridker]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical application of C-reactive protein for cardiovascular disease detection and prevention]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2003</year>
<volume>107</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>363-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakkinen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Abbott]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Curb]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Bl]]></surname>
<given-names><![CDATA[Rodriguez]]></given-names>
</name>
<name>
<surname><![CDATA[Yano]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tracy]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C-reactive protein and myocardial infarction]]></article-title>
<source><![CDATA[J Clin Epidemiol]]></source>
<year>2002</year>
<volume>55</volume>
<page-range>445-51</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jialal]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Devaraj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Venugopal]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C-reactive protein: risk marker or mediator in atherothrombosis?]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2004</year>
<volume>44</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-11</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marcadores de inflamación en enfermedades cardiovasculares]]></article-title>
<source><![CDATA[Medicina &amp; Laboratorio]]></source>
<year>2008</year>
<volume>14</volume>
<numero>11-12</numero>
<issue>11-12</issue>
<page-range>547-56</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palma]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Grünholz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Landaeta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mallea]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico]]></article-title>
<source><![CDATA[Rev Med Chile]]></source>
<year>2017</year>
<volume>145</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>260-3</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ballou]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laboratory evaluation of inflammation]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Ruddy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Sledge]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
</person-group>
<source><![CDATA[Kelley's Textbook of Rheumatology]]></source>
<year>2001</year>
<page-range>697-703</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[JB Saunders Company]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Nam]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Pencina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[D'agostino]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[O'donnell]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2005</year>
<volume>165</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2473-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
